UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor

Molecular cancer therapeutics, 2010-08, Vol.9 (8), p.2344-2353

2010

Volltextzugriff (PDF)

Phe19 modification of HDM2-p53 PPI inhibitors to alleviate CYP3A4 metabolism/mechanism-based inhibition liability

Bioorganic & medicinal chemistry letters, 2022-04, Vol.61, p.128625-128625, Article 128625

2022

Volltextzugriff (PDF)

Discovery of a highly potent orally bioavailable imidazo-[1, 2-a]pyrazine Aurora inhibitor

Bioorganic & medicinal chemistry letters, 2018-05, Vol.28 (8), p.1397-1403

2018

Volltextzugriff (PDF)

Aurora Kinase Inhibitors Based on the Imidazo[1,2-a]pyrazine Core: Fluorine and Deuterium Incorporation Improve Oral Absorption and Exposure

Journal of medicinal chemistry, 2011-01, Vol.54 (1), p.201-210

2011

Volltextzugriff (PDF)

Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases

ACS medicinal chemistry letters, 2010-08, Vol.1 (5), p.204-208

2010

Volltextzugriff (PDF)

Structure-guided discovery of cyclin-dependent kinase inhibitors

Biopolymers, 2008-05, Vol.89 (5), p.372-379

2008

Volltextzugriff (PDF)

Discovery of Novel 3,3-Disubstituted Piperidines as Orally Bioavailable, Potent, and Efficacious HDM2-p53 Inhibitors

ACS medicinal chemistry letters, 2016-03, Vol.7 (3), p.324-329

2016

Volltextzugriff (PDF)

Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and Wap-ras transgenic mice

Cancer research (Chicago, Ill.), 1998-11, Vol.58 (21), p.4947-4956

1998

Volltextzugriff (PDF)

Discovery of a Potent, Injectable Inhibitor of Aurora Kinases Based on the Imidazo-[1,2-a]-Pyrazine Core

ACS medicinal chemistry letters, 2010-08, Vol.1 (5), p.214-218

2010

Volltextzugriff (PDF)

Bioisosteric approach to the discovery of imidazo[1,2-a]pyrazines as potent Aurora kinase inhibitors

Bioorganic & medicinal chemistry letters, 2011-01, Vol.21 (1), p.592-598

2011

Volltextzugriff (PDF)

Pyrazolo[1,5- a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2

Bioorganic & medicinal chemistry, 2007-11, Vol.17 (22), p.6220-6223

2007

Volltextzugriff (PDF)

Analysis of the ERK1,2 transcriptome in mammary epithelial cells

Biochemical journal, 2004-08, Vol.381 (Pt 3), p.635-644

2004

Volltextzugriff (PDF)

Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors

Bioorganic & medicinal chemistry, 2007-11, Vol.17 (22), p.6216-6219

2007

Volltextzugriff (PDF)

Design and synthesis of novel fluoro amino acids: synthons for potent macrocyclic HCV NS3 protease inhibitors

Tetrahedron letters, 2010-06, Vol.51 (23), p.3057-3061

2010

Volltextzugriff (PDF)

Supervision for staff development: Ideas and application

Doll, Ronald C

1983

Volltextzugriff (PDF)

Towards the second generation of Boceprevir: Dithianes as an alternative P2 substituent for 2,2-dimethyl cycloproyl proline in HCV NS3 protease inhibitors

Bioorganic & medicinal chemistry letters, 2010-03, Vol.20 (5), p.1689-1692

2010

Volltextzugriff (PDF)

Inhibition of cyclin-dependent kinases - a review of the recent patent literature

Recent patents on anti-cancer drug discovery, 2006-11, Vol.1 (3), p.357-367

2006

Volltextzugriff (PDF)

Effect of fluoxetine, pemoline and placebo on heart period and QT variability in normal humans

Journal of psychosomatic research, 2003-09, Vol.55 (3), p.247-251

2003

Volltextzugriff (PDF)

Discovery of C-imidazole azaheptapyridine FPT inhibitors

Bioorganic & medicinal chemistry letters, 2010-02, Vol.20 (3), p.1134-1136

2010

Volltextzugriff (PDF)

Mass spectrometric studies of potent inhibitors of farnesyl protein transferase--detection of pentameric noncovalent complexes

Journal of mass spectrometry., 2008-10, Vol.43 (10), p.1393-1401

2008

Volltextzugriff (PDF)

Tricyclic Farnesyl Protein Transferase Inhibitors: Crystallographic and Calorimetric Studies of Structure−Activity Relationships

Journal of medicinal chemistry, 1999-06, Vol.42 (12), p.2125-2135

1999

Volltextzugriff (PDF)

(+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]- pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamide (SCH-66336): A Very Potent Farnesyl Protein Transferase Inhibitor as a Novel Antitumor Agent

Journal of medicinal chemistry, 1998-11, Vol.41 (24), p.4890-4902

1998

Volltextzugriff (PDF)

The Farnesyl Transferase Inhibitor SCH 66336 Induces a G2 → M or G1 Pause in Sensitive Human Tumor Cell Lines

Experimental cell research, 2001-01, Vol.262 (1), p.17-27

2001

Volltextzugriff (PDF)

Guiding farnesyltransferase inhibitors from an ECLiPS ® library to the catalytic zinc

Bioorganic & medicinal chemistry letters, 2006-02, Vol.16 (3), p.507-511

2006

Volltextzugriff (PDF)

SCH529074, a Small Molecule Activator of Mutant p53, Which Binds p53 DNA Binding Domain (DBD), Restores Growth-suppressive Function to Mutant p53 and Interrupts HDM2-mediated Ubiquitination of Wild Type p53

The Journal of biological chemistry, 2010-04, Vol.285 (14), p.10198-10212

2010

Volltextzugriff (PDF)

1 – 25 von 136

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(111)
Mit Volltextzugriff
(114)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(136)
Japanisch
(12)

Erscheinungsjahr

n.n

Thema

Science & Technology
(82)
Life Sciences & Biomedicine
(68)
Humans
(40)
Animals
(36)
Biological And Medical Sciences
(36)
Medical Sciences
(33)
Pharmacology & Pharmacy
(33)
Chemistry, Medicinal
(27)
Physical Sciences
(27)
Chemistry
(26)
Female
(22)
Chemistry, Organic
(21)
Pharmacology. Drug Treatments
(18)
Male
(17)
Mice
(17)
Alkyl And Aryl Transferases - Antagonists & Inhibitors
(14)
Enzyme Inhibitors - Pharmacology
(14)
Structure-Activity Relationship
(14)
Antineoplastic Agents
(13)
Antineoplastic Agents - Pharmacology
(12)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor

Phe19 modification of HDM2-p53 PPI inhibitors to alleviate CYP3A4 metabolism/mechanism-based inhibition liability

Discovery of a highly potent orally bioavailable imidazo-[1, 2-a]pyrazine Aurora inhibitor

Aurora Kinase Inhibitors Based on the Imidazo[1,2-a]pyrazine Core: Fluorine and Deuterium Incorporation Improve Oral Absorption and Exposure

Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases

Structure-guided discovery of cyclin-dependent kinase inhibitors

Discovery of Novel 3,3-Disubstituted Piperidines as Orally Bioavailable, Potent, and Efficacious HDM2-p53 Inhibitors

Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and Wap-ras transgenic mice

Discovery of a Potent, Injectable Inhibitor of Aurora Kinases Based on the Imidazo-[1,2-a]-Pyrazine Core

Bioisosteric approach to the discovery of imidazo[1,2-a]pyrazines as potent Aurora kinase inhibitors

Pyrazolo[1,5- a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2

Analysis of the ERK1,2 transcriptome in mammary epithelial cells

Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors

Design and synthesis of novel fluoro amino acids: synthons for potent macrocyclic HCV NS3 protease inhibitors

Supervision for staff development: Ideas and application

Towards the second generation of Boceprevir: Dithianes as an alternative P2 substituent for 2,2-dimethyl cycloproyl proline in HCV NS3 protease inhibitors

Inhibition of cyclin-dependent kinases - a review of the recent patent literature

Effect of fluoxetine, pemoline and placebo on heart period and QT variability in normal humans

Discovery of C-imidazole azaheptapyridine FPT inhibitors

Mass spectrometric studies of potent inhibitors of farnesyl protein transferase--detection of pentameric noncovalent complexes

Tricyclic Farnesyl Protein Transferase Inhibitors: Crystallographic and Calorimetric Studies of Structure−Activity Relationships

(+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]- pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamide (SCH-66336): A Very Potent Farnesyl Protein Transferase Inhibitor as a Novel Antitumor Agent

The Farnesyl Transferase Inhibitor SCH 66336 Induces a G2 → M or G1 Pause in Sensitive Human Tumor Cell Lines

Guiding farnesyltransferase inhibitors from an ECLiPS ® library to the catalytic zinc

SCH529074, a Small Molecule Activator of Mutant p53, Which Binds p53 DNA Binding Domain (DBD), Restores Growth-suppressive Function to Mutant p53 and Interrupts HDM2-mediated Ubiquitination of Wild Type p53

Suchergebnisse filtern